在ANCA相关血管炎中对obinutuzumab与rituximab进行随机的II期双盲实验医学研究的研究方案:ObiVas
Dominic Paul McGovern1,2, Mark E McClure3,2, Matthew Coates3,2
1Department of Medicine, University of Cambridge, Cambridge, UK dm992@cam.ac.uk rachel.jones154@nhs.net.
BMJ open
|July 17, 2024
概括
这项试验比较了奥比努图祖马布和利图西马布用于ANCA相关血管炎 (AAV) 诱导疗法. 它研究了与鼻相关的淋巴组织中的B细胞枯竭,以潜在地降低AAV复发风险.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 临床试验 临床试验
背景情况:
- 与ANCA相关的血管炎 (AAV) 复发会导致末端器官损伤,需要长时间的免疫抑制.
- 作为AAV的标准诱导疗法Rituximab具有包括高复发率在内的局限性.
- 奥比努图祖马布是一种II型抗CD20抗体,可以提供优异的B细胞枯竭和降低复发风险.
研究的目的:
- 为了比较obinutuzumab和rituximab在蛋白酶3ANCA阳性 (PR3-ANCA) AAV患者中的机械效应.
- 作为主要终点,评估鼻相关淋巴组织 (NALT) 中的B细胞枯竭.
- 评估两种治疗方法的安全性,临床疗效和对免疫生物标志物的影响.
主要方法:
- 一个随机,双盲,II期受控试验 (ObiVas) 涉及26名PR3-ANCA阳性AAV患者.
- 患者在第1天和第15天接受1000毫克rituximab或obinutuzumab,并逐渐减少葡萄糖皮质激素治疗方案.
- 主要终点:从基线到第26周的NALT中CD19+B细胞耗尽. 二级结局包括安全性,疗效和免疫生物标志物分析.
主要成果:
- 招聘开始于2023年1月,预计将于2024年底完成.
- 主要终点分析 (NALT B细胞枯竭) 将在试验完成之前开始.
- 完整的安全性,疗效和免疫生物标志物的结果将在试验完成后报告.
结论:
- 在AAV中,ObiVas试验将提供与Rituximab相比Obinutuzumab的疗效和安全性的关键数据.
- 这些发现可能会为未来的AAV治疗策略提供信息,可能会导致改善患者的治疗结果和减少复发率.
- 这项研究有助于了解AAV治疗中的B细胞枯竭机制.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...


